2.90% Dividend Yield, 14 Years of Dividend Hikes – A Biotech Giant With Blockbuster Drugs And Pipeline Momentum
This company has turned rare disease and oncology treatments into multi‑billion‑dollar franchises while building a pipeline that can offset patent cliffs with new launches. It’s not just about selling pills; it’s about using cash flow from established blockbusters to fund next‑generation therapies in obesity, inflammation, and cardiovascular disease. That mix of proven revenue and pipeline optionality makes it one of the steadier names in biotech for dividend investors.
Amgen (AMGN)
Financial Score: 88 / 99
Quick Tip
To keep your portfolio strong, stay on top of the financials for each company you hold. Solid companies mean better returns, so be sure to check in on their quarterly and annual numbers.Interesting stocks usually score 80+ on the Financial Scale, with top players hitting 90+. If that score dips below 80, it might be a good time to consider cutting ties before things take a turn.Amgen (AMGN) is a Thousand Oaks, California‑based biotechnology company focused on human therapeutics, with a portfolio spanning oncology, inflammation, bone health, cardiovascular disease, and rare diseases. It generated $36.8 billion in 2025 revenue, with products like Repatha, Prolia, and Enbrel driving growth while acquisitions like Horizon bolstered its rare disease footprint. From its 1983 founding as one of the first biotech pioneers, it has evolved into a $150 billion market cap powerhouse balancing mature franchises with pipeline investments.
Dividend profile: big checks with biotech growth
Amgen pays $10.08 per share annually, which delivers a 2.90% yield and a 70.84% payout ratio—high for biotech but sustainable for a company with $7.4 billion in operating cash flow. The 14 consecutive years of dividend growth and +49.00% dividend growth over the last five years show the board is using cash from blockbusters to reward shareholders while funding R&D. It’s balanced because the payout leaves room for acquisitions and pipeline spending, and the absolute dollar amount keeps rising as EPS compounds. This is biotech income done right: not a gimmick, but a real commitment.
Q4 2025: revenue up 9%, GAAP EPS up 111%
For Q4 2025, reported February 3, 2026, Amgen reported total revenues of $9.9 billion, up 9% year over year, with GAAP EPS of $2.45 (up 111% from $1.16) and non‑GAAP EPS of $5.29 (flat from $5.31). GAAP operating income rose to $2.7 billion (up from $2.3 billion), while full‑year 2025 revenues were $36.8 billion (up 10%) and GAAP EPS reached $14.23 (up 88% from $7.56). Non‑GAAP full‑year EPS was $21.84 (up 10%).
Growth levers: volume growth, acquisitions, and obesity pipeline
Amgen delivered 10% revenue growth in 2025, with 18 products hitting record sales and 14 exceeding $1 billion annually, led by double‑digit volume increases in key franchises. The $27.8 billion Horizon acquisition added rare disease revenue, while 2026 guidance calls for revenues of $37.0–$38.4 billion and non‑GAAP EPS of $22.50–$23.50. Pipeline catalysts include obesity candidate MariTide (phase 3 data expected 2026) and CV candidate olpasiran.
Fun Fact – Pioneered the first biotech blockbuster
Amgen launched Epogen (epoetin alfa) in 1989, the first biotech product to top $1 billion in annual sales and kickstarting the era of blockbuster biologics.
Final Take – A biotech dividend with pipeline upside
Amgen offers a 2.90% yield, $10.08 annual dividend, 70.84% payout ratio, 14 years of hikes, and +49.00% 5‑year dividend growth, backed by $36.8 billion in 2025 revenue and $21.84 non‑GAAP EPS. Q4 2025 showed $9.9 billion revenues (up 9%), $2.45 GAAP EPS (up 111%), $5.29 non‑GAAP EPS. Financial Score: 88. That’s a solid level but not bulletproof—companies above 90 are the truly elite tier; risks include patent cliffs and pipeline failures, but cash flow strength and Horizon integration make it a reliable dividend grower.
Someone’s sitting in the shade today because someone planted a tree a long time ago. ― Warren Buffett.
Learn the MaxDividends Way
Start Here
🔑 Explore the Premium Hub (exclusive — upgrade to unlock)
Guides & Step-by-Step
Deep Insights
📖 I ❤️ Dividends: Why I Believe Dividend Investing Is the Best Strategy | E-Book
How Effective is the MaxDividends Strategy for Building Growing Passive Income
Help & Support
Got a question about dividends? Ask Max, your AI Dividend Assistant!
Didn’t get the answer you need? Reach out: max@maxdividends.app or team@maxdividends.app — we’ll help you out.